Warfarin initiation and the potential role of genomic-guided dosing.
作者信息
Lee Craig R
出版信息
Clin Med Res. 2005 Nov;3(4):205-6. doi: 10.3121/cmr.3.4.205.
Abstract
摘要
相似文献
1
Warfarin initiation and the potential role of genomic-guided dosing.
Clin Med Res. 2005 Nov;3(4):205-6. doi: 10.3121/cmr.3.4.205.
2
The pharmocogenomics of warfarin: closing in on personalized medicine.
Mol Interv. 2006 Aug;6(4):223-7. doi: 10.1124/mi.6.4.8.
3
A case report of a patient carrying CYP2C9*3/4 genotype with extremely low warfarin dose requirement.
J Korean Med Sci. 2007 Jun;22(3):557-9. doi: 10.3346/jkms.2007.22.3.557.
4
Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients.
Eur J Clin Pharmacol. 2007 Dec;63(12):1135-41. doi: 10.1007/s00228-007-0381-6. Epub 2007 Sep 27.
5
The cost-effectiveness of warfarin pharmacogenomics.
J Thromb Haemost. 2007 Sep;5(9):1974-5. doi: 10.1111/j.1538-7836.2007.02699.x. Epub 2007 Jul 23.
6
Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin.
Thromb Haemost. 2004 Jan;91(1):87-94. doi: 10.1160/TH03-06-0379.
7
Warfarin-dosing algorithm based on a population pharmacokinetic/pharmacodynamic model combined with Bayesian forecasting.
Pharmacogenomics. 2009 Aug;10(8):1257-66. doi: 10.2217/pgs.09.65.
8
Genetic testing for warfarin dosing? Not yet ready for prime time.
Pharmacotherapy. 2008 Feb;28(2):141-3. doi: 10.1592/phco.28.2.141.
9
Pharmacogenomics of warfarin: uncovering a piece of the warfarin mystery.
Am J Health Syst Pharm. 2009 Jan 15;66(2):123-33. doi: 10.2146/ajhp080127.
10
Q: Should we use pharmacogenetic testing when prescribing warfarin?
Cleve Clin J Med. 2013 Aug;80(8):483-6. doi: 10.3949/ccjm.80a.12184.
本文引用的文献
1
Impact of age, CYP2C9 genotype and concomitant medication on the rate of rise for prothrombin time during the first 30 days of warfarin therapy.
Clin Med Res. 2005 Nov;3(4):207-13. doi: 10.3121/cmr.3.4.207.
2
A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data.
Clin Med Res. 2005 Aug;3(3):137-45. doi: 10.3121/cmr.3.3.137.
3
Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose.
N Engl J Med. 2005 Jun 2;352(22):2285-93. doi: 10.1056/NEJMoa044503.
4
The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Chest. 2004 Sep;126(3 Suppl):204S-233S. doi: 10.1378/chest.126.3_suppl.204S.
5
Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy.
JAMA. 2002 Apr 3;287(13):1690-8. doi: 10.1001/jama.287.13.1690.
Zotero 插件